Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

PubWeight™: 2.42‹?› | Rank: Top 2%

🔗 View Article (PMC 2970800)

Published in J Hepatol on June 12, 2009

Authors

Pippa Newell1, Sara Toffanin, Augusto Villanueva, Derek Y Chiang, Beatriz Minguez, Laia Cabellos, Radoslav Savic, Yujin Hoshida, Kiat Hon Lim, Pedro Melgar-Lesmes, Steven Yea, Judit Peix, Kemal Deniz, M Isabel Fiel, Swan Thung, Clara Alsinet, Victoria Tovar, Vincenzo Mazzaferro, Jordi Bruix, Sasan Roayaie, Myron Schwartz, Scott L Friedman, Josep M Llovet

Author Affiliations

1: Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA.

Articles citing this

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature (2013) 7.51

Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res (2010) 1.43

Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med (2011) 1.33

Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33

Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22

An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening. Dis Model Mech (2011) 1.17

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer (2012) 1.13

Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle (2013) 1.08

Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol (2010) 1.08

MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology (2013) 1.07

Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology (2010) 1.05

Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05

Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis (2010) 1.01

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis (2012) 1.01

Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer (2012) 0.98

Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol (2011) 0.97

LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol Cancer (2013) 0.94

Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol (2012) 0.92

The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer (2010) 0.91

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol (2013) 0.91

Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol (2016) 0.88

Investigation of oncogenic cooperation in simple liver-specific transgenic mouse models using noninvasive in vivo imaging. PLoS One (2013) 0.87

Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol (2015) 0.87

Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol (2011) 0.84

Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1. Gastroenterology (2012) 0.83

The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) (2014) 0.82

Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. PLoS One (2010) 0.82

Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget (2014) 0.81

The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. Free Radic Biol Med (2012) 0.81

Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol (2013) 0.81

Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. J Transl Med (2015) 0.80

Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clin Exp Metastasis (2010) 0.79

Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. Ann Gastroenterol (2015) 0.79

pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncotarget (2016) 0.79

Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma. PLoS One (2013) 0.78

Interactions of everolimus and sorafenib in pancreatic cancer cells. AAPS J (2012) 0.78

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. Oncotarget (2015) 0.78

A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. Funct Integr Genomics (2011) 0.78

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther (2016) 0.78

Show me your signaling--and I'll tell you who you are. J Hepatol (2009) 0.77

Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics (2010) 0.77

Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. Transl Cancer Res (2013) 0.76

Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? World J Gastroenterol (2016) 0.76

Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget (2016) 0.75

Targeting β-catenin in hepatocellular cancers induced by co-expression of mutant β-catenin and K-Ras in mice. Hepatology (2016) 0.75

Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol (2017) 0.75

Comparative analysis of hepatocellular carcinoma and cirrhosis gene expression profiles. Mol Med Rep (2016) 0.75

Gankyrin induces STAT3 activation in tumour microenvironment and sorafenib resistance in hepatocellular carcinoma. Cancer Sci (2017) 0.75

Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice. Cancer Med (2017) 0.75

Articles cited by this

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78

Hepatocellular carcinoma. Lancet (2003) 22.54

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74

Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05

MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95

The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res (2000) 3.93

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91

The dark side of Ras: regulation of apoptosis. Oncogene (2003) 2.60

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53

Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol (2003) 2.36

High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res (2001) 2.07

Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology (2008) 1.97

Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene (2003) 1.27

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26

MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res (2004) 1.21

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21

FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology (2008) 1.20

NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene (2003) 1.17

The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway. J Biol Chem (2006) 1.14

Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol (1992) 1.06

High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int (2005) 1.01

Alterations of the BRAF gene in thyroid tumors. Endocr Pathol (2005) 0.97

BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol (2005) 0.97

CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene (2004) 0.96

Articles by these authors

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

Hepatocellular carcinoma. Lancet (2003) 22.54

Hepatocellular carcinoma. Lancet (2012) 18.09

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33

Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27

Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83

Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut (2012) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28

miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut (2012) 3.67

Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63